Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adaptations of mitochondrial, autophagy and nutrient sensing pathways in the liver from long-lived mice overexpressing CYB5R3 are sex-dependent and involve inter-organ responses.

GeroScience·2025
Same author

Effects of tetrahydroindenoindole supplementation on metabolism: A systematic review with meta-analysis of rodent-based studies.

GeroScience·2025
Same author

Calcium (Ca<sup>2+</sup>) fluxes at mitochondria-ER contact sites (MERCS) are a new target of senolysis in therapy-induced senescence (TIS).

npj aging·2025
Same author

Sex-dependent adaptations in heart mitochondria from transgenic mice overexpressing cytochrome b<sub>5</sub> reductase-3.

Mitochondrion·2025
Same author

CYB5R3 overexpression exhibits sexual dimorphism: Mitochondrial and metabolic adaptations in transgenic female mice during calorie restriction.

Free radical biology & medicine·2024
Same author

Correction to: CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation.

Cellular oncology (Dordrecht, Netherlands)·2023
Same journal

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review 2020-present.

Expert opinion on therapeutic patents·2026
Same journal

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).

Expert opinion on therapeutic patents·2026
Same journal

Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present).

Expert opinion on therapeutic patents·2026
Same journal

A patent review of GPR84 receptor antagonists (2020-present).

Expert opinion on therapeutic patents·2026
Same journal

SLIT2 and ROBO-axis inhibitors for the treatment of cancer: a patent review (2020-2026).

Expert opinion on therapeutic patents·2026
Same journal

New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present).

Expert opinion on therapeutic patents·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates

Published on: February 27, 2016

Sirtuin activators.

Francisco J Alcaín1, José M Villalba

  • 1Universidad de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Facultad de Ciencias, Campus Rabanales, Edificio Severo Ochoa, 3 feminine planta, 14014 Córdoba, Spain.

Expert Opinion on Therapeutic Patents
|May 16, 2009
PubMed
Summary
This summary is machine-generated.

New synthetic compounds are more effective SIRT1 activators than resveratrol, offering potential for treating obesity and age-related decline. These compounds improve insulin response and mitochondrial function, with human trials underway.

Related Experiment Videos

Last Updated: Jun 23, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins (SIRT2) and Specific Protein-substrates

Published on: February 27, 2016

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Sirtuins (SIRT1-7) are NAD(+)-dependent deacetylases regulating key cellular processes.
  • SIRT1 activation by calorie restriction influences lifespan, neuroprotection, metabolism, and insulin secretion.
  • Developing sirtuin activators is a major focus due to their therapeutic potential.

Purpose of the Study:

  • To review the involvement of sirtuins in pathophysiological processes.
  • To explore novel synthetic sirtuin activators.

Main Methods:

  • Literature review of sirtuin involvement in disease.
  • Analysis of synthetic sirtuin activator development.

Main Results:

  • Resveratrol is a potent natural SIRT1 activator, mimicking calorie restriction benefits.
  • New synthetic SIRT1 activators show significantly higher potency than resveratrol.
  • These novel activators enhance insulin sensitivity and mitochondrial function in preclinical models.

Conclusions:

  • Resveratrol shows promise for obesity and age-related conditions but has limitations.
  • Development of bioavailable, targeted sirtuin activators is a promising medicinal chemistry avenue.
  • Ongoing human trials are evaluating improved resveratrol formulations and synthetic SIRT1 activators.